08.02.2013 21:05 Uhr, Quelle: Wallstreet online

RNL BIO filed Phase II/III Clinical Trial with KFDA to Treat Cerebral Palsy Using Autologous Fat Derived Stem Cells

SEOUL, South Korea, Feb. 8, 2013 /PRNewswire/ RNL BIO CO LTD (RNL) announced today the filing of an Investigational New Drug (IND) application with the Korean Food and Drug Administration (KFDA) to initiate clinical trials phase II and III …

Weiterlesen bei Wallstreet online

Digg del.icio.us Facebook email MySpace Technorati Twitter

JustMac.info © Thomas Lohner - Impressum - Datenschutz